Video: Increased reproducibility with KingFisher™ instruments
ESHG 2019 Conference Presentation: Using KingFisher™ to increase reproducibility in new applications using challenging samples.
List view / Grid view
ESHG 2019 Conference Presentation: Using KingFisher™ to increase reproducibility in new applications using challenging samples.
The interaction between a SARS antibody called CR3022 and the COVID-19 coronavirus has been mapped by researchers, revealing a viral vulnerability.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
Cryogenic electron microscopy revealed that the vitamin B12 transporter on Mycobacterium tuberculosis acts like a non-selective sluice, transporting both the vitamin and antibiotics.
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
The TAp63 tumour suppressor protein, two micro RNAs (miRNAs) and the AURKA gene can all suppress cutaneous squamous cell carcinoma (cuSCC) development, find researchers.
Researchers have optimised PROTAC substances to degrade and dispose of proteins that support cancers, by customising their structure and selecting the best ligases.
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
Scientists used optical photothermal spectroscopy (O-PTIR) to image murine neurons affected by early stage Alzheimer’s disease, providing insight into the progression of the disease.
Researchers have identified which SARS-CoV-2 proteins physically associate with proteins in human cells, revealing potential drug targets to treat the COVID-19 coronavirus.
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
Using X-ray crystallography, researchers have revealed the structure of the SARS-CoV-2 main protease, designing an inhibitor to bind to this target and prevent viral replication.
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
Scientists have demonstrated an innovative technique for creating microparticles for tissue engineering out of a combination of disordered and partially ordered proteins.
A new 3D model of the surface of the coronavirus COVID-19 has been released, to aid researchers in the development of a treatment.